All In Biotech

NDA 215887 · Biogen Ma

Qalsody

Tofersen · Intrathecal · Antisense Oligonucleotide

NovelAccelerated approvalPriority reviewOrphan

CDER novel approval, Apr 25, 2023: To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation

Last checked: Nov 20, 2026Latest source record: Apr 25, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Apr 25, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

6

3 Phase 3, 2 recruiting

FAERS reports

567

309 serious, 125 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 23, 2026.

QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 ( SOD1 ) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). QALSODY is an antisense oligonucleotide indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 ( SOD1 ) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). ( 1 )

Mechanism: Tofersen is an antisense oligonucleotide that causes degradation of SOD1 mRNA through binding to SOD1 mRNA, which results in a reduction of SOD1 protein synthesis.

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 25, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
1 products under this application
  • QALSODY · TOFERSEN 100MG/15ML (6.7MG/ML) · SOLUTION, INTRATHECAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tofersen" as an intervention, any sponsor and status, largest first.

All 6 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • amyotrophic lateral sclerosis66
  • death57
  • headache57
  • procedural pain46
  • post lumbar puncture syndrome35
  • fall27
  • csf protein increased26
  • back pain23
  • fatigue23
  • muscular weakness20
  • pain in extremity20
  • pain19

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202357
2024166
2025189
2026155

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Qalsody (Tofersen)

2024 spending

$1.1M

Beneficiaries

11

71 claims

Per beneficiary

$99,927

$990.26 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$454,058
2024$1,099,192

Part B: Qalsody (Tofersen) · HCPCS J1304

2024 spending

$5.8M

Beneficiaries

54

394 claims

Per beneficiary

$108,202

2024 ASP limit $151.54 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$5,842,933

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7 on PubMed

Sponsor: Biogen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.